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Abstract Cyclic AMP down-regulates vesicular monoamine 
transport in PC12 cells and thereby decreased catecholamine 
reuptake from the extracelhilar fluid. We examined the effects 
of protein kinase inhibitors and protein phosphatase inhibitors on 
this cAMP action. Treatment of cells with a protein kinase inhib- 
itor, K252a, increased vesicular amine transport and cellular 
amine uptake, thereby antagonizing the regulatory action of 
cAMP. In contrast, a protein phosphatase inhibitor, okadaic acid, 
had the opposite effect on the amine transport, i.e. it enhanced 
the cAMP action. These results suggest the involvement of a 
protein phosphorylation process in the cAMP-dependent modula- 
tion of vesicular monoamine transport. 
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inhibiting the uptake process of the cells [4]. Furthermore, this 
inhibition was shown to be due to the down-regulation f vesic- 
ular monoamine transport by cAMP [4]. 
In the present study, in order to elucidate the mechanism of
this cAMP action on the vesicular amine transport, we exam- 
ined the effect of protein kinase inhibitors and protein phos- 
phatase inhibitors on cateeholamine uptake by intact PC12 
cells and on vesicular 5-HT uptake by digitonin-perrneabilized 
PC 12 cells. The action of cAMP was inhibited by protein kinase 
inhibitors and enhanced by protein phosphatase inhibitors, 
suggesting the involvement of a protein phosphorylation proc- 
ess in this cAMP-dependent down regulation of vesicular 
monoamine transport. 
2. Experimental 
1. Introduction 
Monoamines such as dopamine and serotonin (5-HT) in neu- 
ronal ceils are synthesized in the cytosolic ompartment and, 
therefore, have to be transported in secretory vesicles for exocy- 
totic release. On the other hand, cellular ability to reuptake 
extracellular mines is dependent on activities of amine trans- 
port systems in both the plasma membrane and the secretory 
vesicle membrane [1-3]. Since the cyctosolic pool size for the 
amines is rather small [4], amine transport from the cytosol to 
vesicles is required to allow continuous reuptake of extracellu- 
lar amines. Many psychostimulants and sympathomimetic 
agents uch as amphetamine increase xtracellular mine levels 
in terminal dopaminergic areas of the brain [5] by disturbing 
the amine storage in the secretory vesicles [6,7]. Thus, vesicular 
monoamine transport iscrucial for exocytotic release and reup- 
take of amines, both of which processes determine the extracel- 
lular amine levels and hence neuronal activities. In a previous 
study, we demonstrated that treatment ofPC 12 cells with dibu- 
tyryl cyclic AMP (dBcAMP) or other agents that elevate cellu- 
lar cAMP increased the extracellular catecholamine level by 
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Abbreviations: dBcAMP, dibutyryl cyclic AMP; NE, norepinephrine; 
5-HT, serotonin; HPLC, high-performance liquid chromatography; 
PCA, perchloric acid; HTMS buffer, 20 mM HEPES-Tris, pH 7.4/6 
mM magnesium chloride/0.32 M sucrose. 
2.1. Pheochromocytoma cellculture 
PC12 cells were cultured in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 7% fetal bovine serum, 7% horse serum, 
100/2g/ml streptomycin, and 100 units/ml penicillin [8]. Cells were 
seeded in 3.5-cm plastic dishes or 12-well plates and used for experi- 
ments 2 or 3 days later. 
2.2. Norepinephrine (NE) uptake by intact cells 
Catecholamines were measured asdescribed previously [4,9]. In brief, 
PC12 cells in 3.5-cm dishes were incubated in a COz incubator for 60 
rain with 1 ml of culture medium containing 1/2g/ml of NE (5.92/2M). 
The cells were then washed with 1 ml each of the culture medium and 
serum-free DMEM. NE incorporated into the ceils was extracted with 
0.5 ml of 0.1 M PCA/1 mM EDTA/0.1% sodium bisulfite. Precipitated 
proteins were removed by brief centrifugation, and a 10-/21 sample of 
the supernatant was analyzed on a high-performance liquid chroma- 
tography (HPLC) apparatus equipped with an electrochemical detector 
(Coulochem Model 5100A). The precipitate was dissolved in 1 M 
NaOH and used for protein determination bythe Bradford method 
[10]. 
2.3. Serotonin-uptake by digitonin-permeabilized cells 
PC12 cells were made permeable with digitonin and then subjected 
to an assay of 5-HT uptake as described previously [4,11]. Ceils were 
treated with 100-150/2M digitonin in the culture medium for 15 min 
at 25°C and then washed twice with 1 ml of 50 mM HEPES-Tris, pH 
7.4/6 mM magnesium chloride/0.32 M sucrose (HTMS buffer). Incuba- 
tion for 5-HT uptake was performed in 1 ml of HTMS buffer (1 ml in 
3.5 cm-dish) in the presence and absence of 2 mM ATP at 37°C for 30 
rain. Uptake was initiated by the addition of 5-HT (final 50 pM), and 
stopped by removing the uptake mixture. This was followed by washing 
the cells twice with 1 ml of HTMS buffer. Incorporated 5-HT was 
extracted with 250/21 of 0.1 M PCA/1 mM EDTA/0.1% sodium bisulfite 
and determined by HPLC using a fluorescence d tector according to 
Hasegawa and Ichiyama [12] or by an HPLC apparatus equipped with 
an electrochemical detector (Eicom ECD-100) [11]. 
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3. Results 
3.1. Norepinephrine uptake by intact cells 
In order to test a possible involvement of  protein phospho- 
rylation in the regulation ofcatecholamine transport by cAME 
we examined the effects of  inhibitors of  protein kinase and of 
protein phosphatase. K252a, a protein kinase inhibitor, in- 
creased the NE  uptake activity of  intact PC12 cells and antag- 
onized the inhibitory effect of  dBcAMP or forskolin when used 
in combination with either of  these compounds (Fig. 1A). Stau- 
rosporin, another kinase inhibitor, also increased the catechol- 
amine uptake to about 140% at a dose of  2.0 pM. The stimula- 
tory effect of  K252a on NE  uptake was concentration de- 
pendent in either the presence or absence of  dBcAMP, but the 
dose-response curve in the presence of dBcAMP shifted down 
and rightward (Fig. 1B); i.e., dBcAMP suppressed the uptake 
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Fig. 1. Effect of K252a on cAMP inhibition of norepinephrine (NE) 
uptake by intact PC12 cells. (A) Effect of K252a on dBcAMP- and 
forskolin-dependent inhibition of the NE uptake. PC12 cells cultured 
in 3.5 cm dishes were incubated with 1 ,ug/ml (=5.92/zM) NE for 60 
rain in the presence of 1 mM dBcAMP (dB), 50/tM forskolin (Forsk), 
2.14 pM K252a, the combination of K252a and dB or Forsk, or in the 
absence of any of them (Cont), in a COz incubator. K252a was added 
simultaneously to the medium when used in combination with either 
dBcAMP or forskolin. Values are the means _+ S.E.M. (n = 5). ****Dif- 
ferent from the control value at P < 0.001 (Student's t-test). (B) Effect 
of K252a concentration on NE uptake in the presence (o) and absence 
(o) of 1 mM dBcAMP. NE uptake by PCI2 cells in 3.5-cm dishes was 
measured in the presence of various concentrations of K252a as de- 
scribed above. Values are the means -!-_ S.E.M. (n = 4). 
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Fig. 2. Effect of phosphatase inhibitors on cAMP inhibition of norep- 
inephrine (NE) uptake by intact PC 12 cells. (A) Effects of calyculin A 
and okadaic acid on NE uptake. PC12 cells in 3.5 cm dishes were 
incubated for 60 rain with 1 pg/ml NE in the absence (Cont), and 
presence of 1 mM dBcAMP (dB), 0.62/t M okadaic acid (OA), 10 nM 
calyculin A (Cal), dBcAMP plus okadaic acid, or dBcAMP plus ca- 
lyculin A in a CO2 incubator. The effect of okadaic acid (0.62 pM) was 
also examined in the presence of 2.14 pM K252a. Values are the 
means _+ S.E.M. (n = 4). Different from the respective control values at: 
***P < 0.01 and **P < 0.02 (Student's t-test). (]3) Effect of okadaic 
acid concentration. NE uptake activity of intact PC12 cells was meas- 
ured as above in the presence of various concentrations of okadaic acid 
with (o) or without (o) 1 mM dBcAMP. Values are the means + S.E.M. 
(n = 4). 
activity of  the cells, and thus a higher dose of  K252a was 
required to overcome the effect o fdBcAMP and to increase the 
uptake process. These results are compatible with the hypothe- 
sis that the inhibitory effect of  cAMP on vesicular monoamine 
transport is mediated by protein phosphorylation and suggest 
the possibility that some protein(s) being involved in the regu- 
lation of the amine transport is partly phosphorylated by 
K252a-sensitve kinase(s) even without the dBcAMP treatment. 
In contrast, inhibitors of  protein phosphatase showed an 
opposite effect to that of  protein kinase inhibitors on NE  up- 
take. Okadaic acid (0.62 pM) and calyculin A (40 nM) inhibited 
NE  uptake by PC12 cells by about 25% and 10%, respectively 
(Fig. 2A). In the presence of  dBcAMP, okadaic acid showed 
greater inhibition at all doses examined (up to 0.62 pM,  Fig. 
2B). Calyculin A behaved similarly to okadaic acid in the pres- 
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Fig. 3. Effect of protein kinase inhibitors and a protein phosphatase 
inhibitor on vesicular monoamine transport by digitonin-permeabilized 
PC12 cells. (A) Effect of protein kinase inhibitors. PC12 cells in12-well 
plates were cultured for 30 min in the presence of 1 mM dBcAMP (dB), 
2.14/zM K252a, dBcAMP plus K252a, 2 ,uM staurosporin (Stauro), 
dBcAMP plus staurosporin, or one of them (Cont) for 30min in a CO2 
incubator. The cells were thenpermeabilized by digitonin treatment a d
then incubated with 50/~M 5-HT in the presence and absence of 2 mM 
ATP for 30 min at 25°C. Vesicular monoamine transport was measured 
as ATP-dependent 5-HT uptake, which was calculated by subtracting 
the 5-HT uptake obtained in the absence of ATP from that obtained 
in the presence of ATE Values are the means + S.E.M. (n =4). 
(B) Effect of okadaic acid. PC12 cells cultured in 12-well plates were 
cultured for 30 rain in the presence of 1 mM dBcAMP, 0.62#M okadaic 
acid (OA), or dBcAMP plus okadaic acid, or in the absence of any of 
them (Control) for 30 rain in a CO2 incubator. Vesicular 5-HT uptake 
was measured as described above after the digitonin-permeabilization 
of the cells. Values are the means + S.E.M. (n = 4). In (A) and (B), 
significant differences from each control value are marked: 
***P < 0.01, **P < 0.02, and*P < 0.05 (Student's t-test). 
ence of dBcAMR Higher doses of both okadaic acid and ca- 
lyculin A were not used because PC12 cells lost adhesion to the 
culture dish at high concentrations of the agents. These results 
together with those obtained with protein kinase inhibitors 
suggest that the rate of catecholamine uptake by PC12 cells is 
regulated by a balance of protein phosphorylation and 
dephosphorylation activities and that cAMP inhibition of cat- 
echolamine transport was due to stimulation of protein phos- 
phorylation, probably by protein kinase A. 
3.2. Vesicular monoamine transport: 5-HT uptake by 
permeabilized cells 
In a previous study, we demonstrated that the inhibitory 
effect of cAMP on catecholamine uptake by intact cells resulted 
from the down-regulation f the process of amine transport 
through the secretory vesicular membrane [4]. Since we devel- 
oped an assay method for vesicular monoamine transport by 
using digitonin-permeabilized cells, the plasma membrane of 
which allows free movement of the amines [4,11], we further 
examined the effect of protein kinase inhibitors and protein 
phosphatase inhibitors on vesicular monoamine transport with 
this permeabilized cell system. The vesicular monoamine trans- 
port measured as ATP-dependent 5-HT uptake by permeabil- 
ized PC12 cells was lowered by the pretreatment of intact cells 
with dBcAMP prior to the digitonin-permeabilization (Fig. 3). 
However, previous studies showed that the addition of 
dBcAMP [4] or forskolin [11] to the reaction mixture for 5-HT 
uptake by already permeabilized c lls had no effect on the 
vesicular transport activity. Thus, the inhibitory effect on the 
uptake process caused by dBcAMP treatment remained after 
the permeabilization. Similarly, the stimulatory effect of K252a 
treatment ofintact cells remained after the digitonin-permeabil- 
ization: when PC12 cells were cultured for 30 min in the pres- 
ence of K252a and then permeabilized, significant elevation of 
vesicular 5-HT uptake was observed (Fig. 3A). Addition of 
K252a to the uptake mixture did not affect he vesicular trans- 
port activity. The stimulation of 5-HT uptake by K252a pre- 
treatment was observable atits concentrations as low as 20 nM 
and showing its maximal level at 1-2 tiM. The maximal value 
varied from experiment to experiment, being 120% to 150% of 
the value of control cells. The effect of dBcAMP pretreatment 
on vesicular 5-HT uptake was antagonized by the simultaneous 
addition of K252a to the PC12 culture (Fig. 3A). Staurosporin 
and H-7, both known as protein kinase inhibitors, also showed 
effects similar to that of K252a. 
On the other hand, okadaic acid, an inhibitor of protein 
phosphatase, decreased the vesicular monoamine transport, as 
expected from the results with intact PC12 cells. Pretreatment 
of PC12 cells with okadaic acid (0.62 tiM) decreased the vesic- 
ular monoamine transport (ATP-dependent 5-HT uptake) 
measured after the digitonin-permeabilization to about 60% of 
the control. Simultaneous addition of this reagent with 
dBcAMP into the cell culture nhanced the inhibitory effect of 
dBcAMP on vesicular 5-HT uptake (Fig. 3B). Thus, all of the 
results with protein kinase inhibitors and protein phosphatase 
inhibitors trongly suggest that vesicular monoamine transport 
is down-regulated by a cAMP-sensitive protein phosphoryla- 
tion, namely, via a protein kinase A pathway. 
4. Discussion 
Cyclic AMP is known to activate tyrosine hydroxylase, a 
rate-limiting enzyme in catecholamine biosynthesis [13], by 
phosphorylating the enzyme protein via protein kinase A action 
[14-16], thereby increasing the DA production in PC12 cells 
[4,15]. However, as we demonstrated in a previous study [4], 
cAMP also down-regulated the monoamine transport through 
secretory vesicle membranes. Thus, cAMP influenced the intra 
and extracellular catecholamine levels not only by stimulating 
its synthesis but also by regulating vesicular monoamine trans- 
port. In the present study, we examined the effect of protein 
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kinase inhibitors and protein phosphatase inhibitors on this 
cAMP action on vesicular monoamine transport and catecbol- 
amine uptake activity of PC12 cells, since the majority of the 
regulatory actions of cAMP are mediated via protein kinase 
A-dependent protein phosphorylation [ 17]. Vesicular monoam- 
ine transport was measured as ATP-dependent 5-HT uptake by 
digitonin-permeabilized PC 12 cells [4]. A protein kinase inhibi- 
tor, K252a, antagonized and a protein phosphatase inhibitor, 
okadaic acid, enhanced the dBcAMP effect on the vesicular 
amine transport measured in the permeabilized cell system (Fig. 
3), supporting the idea that protein phosphorylation is involved 
in the mechanism of the cAMP action. As the amine storage 
capacity of the vesicular compartment is far larger than the 
cytosolic pool size [4], the effects of either of dBcAMP, protein 
kinase inhibitors, or protein phosphatase inhibitors on vesicu- 
lar monoamine transport are necessarily reflected in the cellular 
uptake of catecholamines from the medium. Indeed, the in ib- 
itory effect of dBcAMP on NE uptake by intact cells was 
antagonized by K252a, and strengthened by okadaic acid and 
calyculin A. Furthermore, in the absence of dBcAMP, K252a 
and okadaic acid enhanced and inhibited, respectively, the NE 
uptake by intact PC 12 cells in a concentration-dependent man- 
ner (Figs. 1 and 2). These results suggest hat vesicular amine 
transport and hence catecholamine uptake activity of the cells 
is regulated by a balance of protein-phosphorylating a d - 
dephosphorylating activities, or the level ofphosphorylation f 
a certain protein(s) responsible for the control of vesicular 
amine transport. In addition, a significant fraction of such 
protein(s) is suggested to be present in the phosphorylated state 
even without dBcAMP treatment of the cells, since K252a alone 
was able to increase vesicular 5-HT transport and NE uptake 
activities of the cells, cAMP may down-regulates vesicular 
monoamine transport by elevating the phosphorylation level of 
such a protein(s) via the protein kinase A pathway. It is yet to 
be elucidated what protein(s) is the target for phosphorylation 
and whether it is phosphorylated directly by protein kinase A 
or via some protein phosphorylation cascade. Recently, 
cDNAs for the chromaffin granule amine transporter and the 
synaptic vesicle amine transporter were cloned and sequenced 
[18-21]. Both types of these vesicular monoamine transporters 
were shown to contain consensus equences for phosphoryla- 
tion by protein kinase A in their cytoplasmic domains [18,20]. 
This is of particular interest to us since the vesicular monoam- 
ine transporter would be the one to be examined as the target 
of cAMP-dependent regulation because of its primary role in 
vesicular monoamine transport. 
Regulation of the extracellular level of neurotransmitters is 
crucial for neuronal activity. Many of the sympathomimetic 
agents, antidepressants, and psychostimulants are known to 
elevate xtracellular monoamine l vels in the brain by blocking 
the amine transport through either plasma membrane [22] or 
vesicular membrane [5], thus disturbing the amine storage func- 
tion. In PC12 cultures, dBcAMP was more effective in increas- 
ing extracellular DA than amine transport inhibitors uch as 
reserpine and nomifensine, since cAMP stimulated, at the same 
time, the de novo DA synthesis besides inhibiting vesicular 
amine transport. The observed effect of dBcAMP on extra and 
intracellular catecholamine l vels in PC12 cell,~ suggests that 
cAMP functions in a similar fashion also in catecholaminergic 
and serotonergic neurons of central nervous system and that 
it, thereby, participates in intrinsic mechanisms for antidepres- 
sant or psychostimulant activity. Indeed, infusion of 8-bromo- 
cAMP or forskolin by the brain microdialysis technique was 
reported to increase the DA level in a dialysate from rat stria- 
turn [23]. We also observed by brain microdialysis the increased 
DA output by dBcAMP infusion of the rat striatum. Further- 
more, dBcAMP, unlike high K+, maintained the extracellular 
DA at a high level as long as the perfusion with the agent was 
continued (N. Nakanishi et al., unpublished results). 
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